Trial Search Results

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seagen Inc.

Collaborator: Genentech, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: SGN-40
  • Drug: placebo
  • Drug: rituximab
  • Drug: etoposide
  • Drug: carboplatin
  • Drug: ifosfamide

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Confirmed diagnosis of de novo or transformed DLBCL, or follicular grade 3b lymphoma.

   - Received at least four cycles of first-line therapy with R-CHOP, or equivalent.

   - Best clinical response to first-line therapy of stable disease, partial response, or
   complete response.

   - At least one measureable lesion that is both greater than or equal to 1.5cm by
   radiographic imaging and by positive FDG-PET scan.

Exclusion Criteria:

   - Leptomeningeal or central nervous system lymphoma.

   - Received any therapy for relapsed or progressive disease except for local radiation,
   steroids, or rituximab.

   - Received a hematopoietic stem cell transplant.

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sipra Choudhury
6507362563
Not Recruiting